Remove Pharmacokinetics Remove Research Remove Trials
article thumbnail

Applying Artificial Intelligence to Transform the Patient Enrollment Paradigm in Clinical Research

PPD

AI also has the potential to incorporate real-world data (RWD) obtained from electronic health records (EHRs), medical claims or other data sources to inform the design and optimization strategy of clinical trials. A high-risk participant can be even excluded from the study based on the severity of the adverse event.

article thumbnail

Establishing Effective Adaptive Trial Designs for Oncology in Multi-Regional Studies

Conversations in Drug Development Trends

Authors: Matt Cooper, PhD, Executive Director, Therapeutic Strategy Lead, Oncology; Megan Morrison, Vice President, Asia Pacific Strategy Lead Adaptive trial designs have become essential in oncology, offering a flexible and efficient approach for conducting clinical trials.

Trials 80
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New drug triggers rapid cell death in cancer models

Broad Institute

Related groups Center for the Development of Therapeutics (CDoT) A team of researchers at Broad Institute of MIT and Harvard, in a long-term project that has included industry collaborators at Bayer and Trueline Therapeutics, has developed a compound called BRD-810 that holds promise as a therapeutic candidate for cancer.

Drugs 133
article thumbnail

PPD Early Development Services: Accelerating the Clinical Process

PPD

As the PPD clinical development business of Thermo Fisher Scientific, we have access to integrated, end-to-end clinical trial support and delivery solutions. What differentiates PPD Early Development services from others in this space? organ impairment, CNS and rheumatology), special populations (e.g.

article thumbnail

De-risking drug discovery with predictive AI

Broad Institute

Still, more than 90 percent of drug candidates fail in clinical trials, with even more that never make it to the clinical stage. Researchers at the Broad Institute of MIT and Harvard have developed AI models that can screen the potential biological effects of drugs before they ever enter a living organism. A fourth is in the works.

article thumbnail

Inside The Altascientist Issue 41: Immunomodulation Assessments for Clinical Trials–Sophisticated Bioanalytical Approaches to Support Complex Modalities

Alta Sciences

Featuring two scenarios that explore the complexities of bioanalysis for immunomodulators, The Altascientist offers practical considerations for ensuring accurate bioanalysis, as well as pharmacokinetic, pharmacodynamic , and safety data in clinical trials.

article thumbnail

New molecular insights on medical cannabis

Drug Target Review

2 Implication of ATX in a large range of human diseases have been highlighted by both fundamental research and clinical trials. 1-5 Implication of ATX in a large range of human diseases have been highlighted by both fundamental research and clinical trials.